Hanane Boucherit

Hanane Boucherit

Auto-generated profile, based on publicly available information

Hanane Boucherit

Laboratory of Applied Biochemistry, Department of Biochemistry and Cellular and Molecular Biology, Faculty of Natural and Life Sciences, Mentouri Brothers University, Constantine 1, Algeria

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2017 in Molecular Informatics
Verified
Journal Article
Closed access
PDF file
AMAmina Merzoug
Amina Merzoug
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
HBHanane Boucherit
Hanane Boucherit
SEZER OKAYSEZER OKAY
SEZER OKAY

3 September 2020 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
HBHanane Boucherit
Hanane Boucherit
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
AMAmina Merzoug
Amina Merzoug
jean Michel Bruneljean Michel Brunel
jean Michel Brunel
Background: The great emergence of multi-resistant bacterial strains and the low renewal of antibiotics molecules are leading human and veterinary medicine to certain therapeutic impasses. Therefore, there is an urgent need to find new therapeutic alternatives including new molecules in the current treatments of infectious diseases. Methionine aminopeptidase (MetAP) is a promising target for developing new antibiotics because it is essential for bacterial survival. Objective: To screen for potential MetAP inhibitors by in silico virtual screening of the ZINC database and evaluate the best potential lead molecules by in vitro studies. Methods: We have considered 200,000 compounds from the ZINC database for virtual screening with FlexX software to identify potential inhibitors against bacterial MetAP. Nine chemical compounds of the top hits predicted were purchased and evaluated in vitro. The antimicrobial activity of each inhibitor of MetAP was tested by the disc-diffusion assay against one Gram-positive (Staphylococcus aureus) and two Gram-negative (Escherichia coli & Pseudomonas aeruginosa) bacteria. Among the studied compounds, compounds ZINC04785369 and ZINC03307916 showed promising antibacterial activity. To further characterize their efficacy, the minimum inhibitory concentration was determined for each compound by the microdilution method which showed significant results. Results: These results suggest compounds ZINC04785369 and ZINC03307916 as promising molecules for developing MetAP inhibitors. Conclusion: Furthermore, they could therefore serve as lead molecules for further chemical modifications to obtain clinically useful antibacterial agents.

19 October 2019 in Current Enzyme Inhibition
Verified
Journal Article
Open access
PDF file
AMAmina Merzoug
Amina Merzoug
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
HBHanane Boucherit
Hanane Boucherit
SHSawsen Hadef
Sawsen Hadef
Aim and Objective: The antibacterial therapy resistance poses an urgent threat to the public’s health. Peptide deformylase is a favorable target to identify new antibiotics with novel mechanism of action. Materials and Methods: In order to discovery new potent inhibitors of this enzyme, the virtual screening method of Zinc database using the binding site of Enterococcus faecalis peptide deformylase combined with microbiological assay were realized. Results: The strategy undertaken in this study allowed us to identify new products with growth inhibition activity. The best result was obtained for the chemicals 4-(1,3-dioxo-1Hbenzo[de]isoquinolin- 2(3H)-yl)-N-hydroxybutanamide and N-hydroxy-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl) acetamide, they showed good affinities and great antibacterial activities compared to the other studied products. Conclusion: The two most promising compounds can serve as potential antibacterial agents.

20 November 2025 in Computational Biology and Chemistry
Verified
Journal Article
Open access
FKFatima Kamah
Fatima Kamah
BABadis Aouzal
Badis Aouzal
HBHanane Boucherit
Hanane Boucherit
NKNadia Kadjoudj
Nadia Kadjoudj
NCNORHANE CHOUITER
NORHANE CHOUITER
Stefania GarzoliStefania Garzoli
Stefania Garzoli
This study investigated the enzyme inhibitory, antimicrobial, and molecular docking properties of grape seed extracts obtained from three Algerian grape cultivars-Sabel, Red Globe, and Cardinal-harvested at different ripening stages. The extracts demonstrated strong inhibitory activity against urease, α-amylase, and lipase, with variability depending on both cultivar and maturation stage. Cardinal seeds displayed the most potent urease inhibition ((IC₅₀ = 3.37 µg/mL) at the BV stage, surpassing the reference thiourea (7.27 ± 1.04 µg/mL), whereas α-amylase inhibition was consistently higher than the commercial inhibitor acarbose with the best activity recorded in RG at repining stage (IC₅₀ = 31.94 µg/mL). Lipase inhibition was markedly enhanced at the late ripening stage for Sabel and Cardinal, highlighting maturation as a critical determinant of bioactivity. Docking simulations revealed that catechin, luteolin, and resveratrol established stable interactions with catalytic residues of pancreatic lipase, supporting the in vitro findings. ADME/Tox predictions confirmed favorable pharmacokinetic properties and low toxicity for most compounds. Antimicrobial assays further demonstrated cultivar-dependent activity against multidrug-resistant Escherichia coli, Candida albicans, and Aspergillus niger, with Cardinal and Red Globe showing the strongest effects with the highest inhibition zones up to 19 mm against multidrug-resistant E. coli. Together, these results highlight grape seeds as a significant reservoir of bioactive substances with possible uses in managing metabolic disorders, infections, and obesity.

1 January 2013 in Trends in Bioinformatics
Verified
Journal Article
Closed access
AMAmina Merzoug
Amina Merzoug
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
KHKhadidja Soulef Hio
Khadidja Soulef Hio
HBHanane Boucherit
Hanane Boucherit
STSoumia Teniou
Soumia Teniou
The drug resistance is a serious problem in malaria. So, the present strategy for new drug development is directed towards identifying essential enzyme systems in the parasite and developing potent molecules to inhibit them. A peptide deformylase (PDF) gene was identified in the Plasmodium falciparum genome and was suggested as a new target for antimalarial therapy. The aim of this study was to analyze the interactions between the PDF of Plasmodium falciparum (pfPDF) and the actinonin, naturally occurring PDF inhibitors to explore their binding modes and to make tests of modelling with a view to identify novel and more efficient antimalarial drugs. The binding modes have been studied using molecular docking software FlexX. The study of the modelling realized on the actinonin shows that the binding energy can be decreased in a significant way by a judicious choice of fragments to be substituted. Replacement of the hydroxymethyl group of the pfPDF inhibitor with an hydroxyl and the Pentyl group by a cyclopentyl-ethyl enhances the binding energy from-24.73 to -35.11 kJ mol-1. The biological potentialities of these proposed compounds were checked by their pharmacokinetic properties and they showed no toxicity.

1 May 2024 in Current Drug Discovery Technologies
Verified
Journal Article
Closed access
PDF file
IBIlham Boulhissa
Ilham Boulhissa
HBHanane Boucherit
Hanane Boucherit
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
Background:: Developing more potent antibacterial agents is one of the most important tasks of scientists in the health field due to the problem of antibiotic resistance. Among the antibiotic targets, we mention MurA (UDP-N-Acetylglucosamine Enolpyruvyl Transferase), which is a key enzyme of peptidoglycan biosynthesis of the bacterial cell wall. Objective:: Our objective was to search for new inhibitors of the bacterial enzyme MurA by docking the analogues of its inhibitor T6361, a derivative of 5-sulfonoxy-anthranilic acid. Methods:: 990 analogues of T6361 were docked in the first binding site of E.coli MurA (open form) using the FlexX program, and the ADME-Toxicity profile of the best ones was evaluated by SwissADME and PreADMET web servers. Results:: Docking results revealed two T6361 analogues to provide better energy scores than T6361, and have similar interactions with the binding site of E.coliMurA namely,3-{[2-(piperidine-1-carbonyl) phenyl]sulfamoyl}benzoic acid and 3-{[2-(pyrrolidine-1 carbonyl)phenyl]sulfamoyl}benzoic acid. Moreover, the two molecules were found to possess good pharmacokinetics and low toxicity. Conclusion:: We propose two analogues of T6361 as new potential inhibitors of MurA enzyme. Their good ADME-Toxicity profile qualifies them to reach in vitro and in vivo assays as future lead molecules.